Infectious disease ·
PAHO confirms U.S. loss of measles elimination status; new TB regimens advance in phase 2; seasonal R21 vaccination cuts malaria

Listen to this post
read by AI voices · all episodesTHE SHORT READ
The Pan American Health Organization (PAHO) said Nov. 17 that endemic measles transmission had been re-established in Bolivia, Mexico and the United States, which lost elimination status. Two 16-week tuberculosis regimens showed potential efficacy in a phase 2 trial and seasonal mass R21/Matrix-M vaccination cut malaria infection in West Africa.
THE DETAILS
- Public health Nov 17, 2026The Pan American Health Organization (PAHO) said Nov. 17 that its regional re-verification commission determined endemic measles transmission had been re-established in Bolivia, Mexico and the United States, and that all three lost elimination status, confirming earlier news reports. The region had reported 58,213 confirmed cases as of Nov. 13. The Centers for Disease Control and Prevention (CDC) counted 5,838 confirmed U.S. cases in 2026 as of Nov. 19. CDC Director Erica Schwartz said the elimination designation is not what protects Americans and that vaccination does, Contagion Live reported.
- Public health Nov 17, 2026More than 11,000 cases and 5,400 deaths have been reported in the Bundibugyo virus disease outbreak in the Democratic Republic of the Congo (DRC), the director-general of the World Health Organization (WHO) said Nov. 17 in opening remarks to the third International Health Regulations Emergency Committee meeting on the outbreak. Between 400 and 500 new cases are still reported every week, and children account for more than a quarter of confirmed cases and one third of deaths, he said. A vaccine trial using Ervebo, which is approved for Ebola virus but not for Bundibugyo virus, began last month, he said.
- Research Nov 19, 2026The phase 2 PARADIGM4TB trial, published online Nov. 19 in the New England Journal of Medicine, randomized 401 participants with tuberculosis to standard isoniazid-rifampin-pyrazinamide-ethambutol (HRZE) for 24 weeks or new four-drug combinations for 16 weeks. On the primary end point, the log10(time to positivity) slope, the relative difference versus HRZE was 20.5% (95% credible interval 2.7 to 41.1) with BTZ-043-bedaquiline-delamanid-moxifloxacin and 9.1% (95% credible interval -8.6 to 29.0) with the ganfeborole regimen. The authors said both showed evidence of potential efficacy; grade 3 or higher adverse events occurred in 38%, 28% and 24% of the ganfeborole, BTZ-043 and HRZE groups.Sources: New England Journal of Medicine, PubMed
- Public health Nov 20, 2026Oregon reported its first influenza A(H5) case associated with a dairy worker, an adult at a commercial dairy cattle farm, the Centers for Disease Control and Prevention (CDC) said in its Nov. 20 FluView report. The worker developed eye irritation, according to CDC, and was treated with oseltamivir and did not require hospitalization, CIDRAP reported. The case was related to an outbreak at a Morrow County dairy farm, according to CIDRAP. It is the fourth influenza A(H5) case in a dairy worker reported in 2026, according to CDC.
- Research Nov 19, 2026In an open-label, cluster-randomized trial published online Nov. 19 in The Lancet, 54 medium-sized villages in The Gambia and Burkina Faso were randomized to seasonal mass vaccination with R21/Matrix-M or no mass vaccination. Vaccination reduced the odds of malaria infection by 70% in The Gambia (adjusted odds ratio 0.30, 95% CI 0.20 to 0.44; P < .0001) and by 25% in Burkina Faso (0.75, 95% CI 0.58 to 0.98; P = .036). The authors said it reduced malaria prevalence in both settings.Sources: The Lancet, PubMed
The weekly innovation roundup for infectious disease, published every Sunday for the week before; every item links to its sources. Latest infectious disease news · All specialties